Qingda granule prevents obesity-induced hypertension and cardiac dysfunction by inhibiting adverse Akt signaling

Qian Gao1, En Ma2, Jinxiao Chen1

  • 1Fujian Key Laboratory of Integrative Medicine on Geriatric, Academy of Integrative, Medicine, Fujian University of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.

Heliyon
|December 29, 2022
PubMed

Insights

Qingda granule (QDG) effectively lowers blood pressure and protects the heart in obesity models. This Traditional Chinese Medicine formula prevents obesity-related hypertension and cardiac dysfunction by inhibiting the Akt signaling pathway, showing safety for long-term use.

Area of Science:

  • Integrative Medicine
  • Cardiovascular Research
  • Metabolic Disease Research

Background:

  • Rising global obesity rates contribute to hypertension and cardiovascular diseases.
  • Effective long-term treatments for obesity and its complications are lacking.
  • Qingda granule (QDG), a Traditional Chinese Medicine, is used for hypertension but its role in obesity-induced conditions needs investigation.

Purpose of the Study:

  • To investigate the efficacy of QDG in preventing and treating obesity-induced hypertension and cardiac dysfunction.
  • To elucidate the underlying mechanism of QDG's protective effects against metabolic disorders.
  • To assess the safety and feasibility of long-term QDG administration.

Main Methods:

  • Established mouse models of obesity using a 16-week high-fat high-fructose diet (HFFD).
  • Administered QDG or saline to mice on HFFD or normal diet.
  • Assessed blood pressure, cardiac function, cardiac hypertrophy, and Akt signaling pathway activation.

Main Results:

  • QDG significantly reduced blood pressure in HFFD-fed mice.
  • QDG improved cardiac function and prevented cardiac hypertrophy.
  • QDG inhibited the adverse chronic activation of the Akt signaling pathway.
  • Long-term QDG treatment showed no side effects and prevented organ damage.

Conclusions:

  • QDG demonstrates potent anti-hypertensive and cardioprotective effects in obesity models.
  • QDG prevents obesity-induced hypertension and cardiac dysfunction by modulating the Akt signaling pathway.
  • QDG is a safe and effective therapeutic option for metabolic diseases like obesity-induced hypertension.

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
680
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
503
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.8K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.5K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
731